Seasonal Influenza Therapeutics (SIT) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape

Seasonal Influenza Therapeutics (SIT) Marketed and Pipeline Drugs Report Overview

Influenza, often referred to as the flu, is an acute infection caused by one of the three closely related viruses designated as influenza types A, B, and C.  Influenza infection is normally self-limiting. Symptoms generally last for one to two weeks, but most people infected with influenza do not need or seek medical treatment.

The Seasonal Influenza Therapeutics (SIT) marketed and pipeline drugs market research report provides a data-driven overview of the current and future competitive landscape in SITs. This report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, pricing and reimbursement, late-stage pipeline products with phase transition success rate (PTSR), and the likelihood of approval (LoA) for SITs.

Leading Marketed Drugs for SIT

Some of the leading marketed drugs for influenza are baloxavir marboxil, zanamivir, oseltamivir phosphate, favipiravir, ribavirin, rimantadine hydrochloride, umifenovir, laninamivir, thymalfasin, and peramivir. The majority of the marketed drugs for the treatment of influenza are exo alpha sialidase inhibitors.

SIT Marketed Drugs Segmentation by Mechanisms of Action

Some of the key mechanisms of action for influenza-marketed drugs are enzyme inhibitors, ion channel blockers, and biological factor activator. Enzyme inhibitor was the leading MoA in 2022.

SIT Marketed Drugs Analysis, by Mechanism of Action, 2022 (%)

For more MoA insights into SIT marketed drugs, download a free report sample

SIT Marketed Drugs Segmentation by Routes of Administration

The key routes of administration for SIT marketed drugs are oral, injection, and inhalational. Oral was the most preferred route in 2022.

SIT Marketed Drugs Analysis, by Routes of Administration, 2022 (%)

For more RoA insights into the SIT marketed drugs, download a free report sample

SIT Marketed Drugs Segmentation by Molecule Type

Most of the marketed drugs for SIT are small molecules. Biologics is another significant molecule type in the marketed drugs for SIT.

SIT Marketed Drugs Analysis, by Molecule Type, 2022 (%)

For more molecule type insights into the SIT marketed drugs, download a free report sample

Leading Pipeline Drugs for SIT

Some of the leading pipeline drugs of SIT are nitazoxanide, DAS-181, naltrexone hydrochloride, AV-5080, CD-388, diltiazem, INNA-051, metenkefalin, Neumifil, PrEP-001, TG-1000, and ZSP-1273.

SIT Pipeline Drugs Segmentation by Mechanism of Action

Some of the key mechanisms of action for SIT pipeline drugs are enzyme inhibitor, antigen inhibitor, receptor agonist, ion channel blocker, receptor antagonist, enzyme activator, protein and peptide inhibitor, cells and cell organelle disrupter, toxin inhibitor, and transporter inhibitor. Enzyme inhibitor was the leading MoA in the pipeline in 2022.

SIT Pipeline Drugs Analysis, by Mechanisms of Action, 2022 (%)

For more MoA insights into the SIT pipeline drugs market, download a free report sample

SIT Pipeline Drugs Segmentation by Routes of Administration

The key routes of administration for SIT pipeline drugs are oral, inhalational, injection, and topical. Oral was the most preferred route of administration in 2022.

SIT Pipeline Drugs Analysis, by Routes of Administration, 2022 (%)

For more routes of administration insights for SIT pipeline drugs market, download a free report sample

SIT Pipeline Drugs Segmentation by Molecule Type

The key molecule types for the SIT pipeline drugs are small molecule, biologic, oligonucleotide, and polymer. Small molecule was the leading molecule type in 2022.

SIT Pipeline Drugs Analysis, by Molecule Types, 2022 (%)

For more molecule type insights into the SIT pipeline drugs market, download a free report sample

Top Sponsors in the SIT Marketed and Pipeline Drugs Market

Some of the top sponsors in the SIT marketed and pipeline drugs market are Roche, GlaxoSmithKline, FUJIFILM Toyama Chemical, Tecnofarma, Sun Pharma, Romark Laboratories, Ansun Biopharma, Alla Chem, Signia Therapeutics, TaiGen Biotechnology, Statera Biopharma, Cidara Therapeutics, and others. Among all the sponsors, Johnson & Johnson has sponsored the highest number of clinical trials of all the trials initiated in influenza in the past 10 years.

SIT Marketed Drugs Report Overview

SIT Pipeline Drugs Market Report Overview

SIT Marketed Drugs MoA Outlook

• Enzyme Inhibitors
• Ion Channel Blockers
• Biological Factor Activator

SIT Marketed Drugs RoA Outlook

• Oral
• Injection
• Inhalational

SIT Marketed Drugs Molecule Types Outlook

• Small Molecule
• Biologics

SIT Pipeline Drugs MoA Outlook

• Enzyme Inhibitor
• Antigen Inhibitor
• Receptor Agonist
• Ion Channel Blocker
• Receptor Antagonist
• Enzyme Activator
• Protein and Peptide Inhibitor
• Cells and Cell Organelle Disrupter
• Toxin Inhibitor
• Transporter Inhibitor

SIT Pipeline Drugs RoA Outlook

• Oral
• Inhalational
• Injection
• Topical

SIT Pipeline Drugs Molecule Types Outlook

• Small Molecule
• Biologic
• Oligonucleotide
• Polymer

Scope

GlobalData’s SIT Marketed and Pipeline Drugs Assessment, Clinical Trials, and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include:

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Retail or Manufacturer Price of Products
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the SIT market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global SIT market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.